/
Our DeepView System uses proprietary AI algorithms to distinguish between fully damaged, partially damaged and healthy human tissue characters invisible to the naked eye, at the initial time point of wound presentation. The DeepView System delivers a binary prediction on the wound s capacity to heal or not-heal by a specified time point in the future.
$1.67
+$0.02 (+1.21%)
EOD Jul 17, 2026
The business is unprofitable at the operating level (-43.78% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 33.6% YoY. Margins deteriorated 21.5pp alongside, both lines moving the wrong way.
Operating margin contracted 21.5pp YoY, cost discipline may be slipping.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$17M
▼ -33.6% YoY
Net Income (TTM)
-$14M
▲ +50.1% YoY
Op. Margin
-57.15%
▼ -21.5pp YoY
ROIC
-77.73%
▲ +178.3pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
-$12M
▼ -7.8% YoY
Net Debt
-$2M
Net Cash Position
Cash & Equiv.
$12M
3Y CAGR: -8.2%
Continue Research
Spectral AI (MDAI)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Spectral AI scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Spectral AI scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 5 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -57.2% operating margin and a -77.7% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh MDAI's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.